Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study

被引：0
|
作者：
Hu, P. [1 ]
Xie, Q. [2 ]
Li, Y. [3 ,11 ]
Chen, X. [4 ,19 ]
Dou, X. [5 ]
Jiang, J. [6 ,20 ]
Shang, J. [7 ]
Zhang, W. [8 ]
Gong, G. [9 ]
Sun, Y. [10 ]
Li, Y. [3 ,11 ]
Liu, Y. [12 ]
Liu, G. [13 ]
Mao, D. [14 ]
Chi, X. [15 ]
Tang, H. [16 ]
Li, X. [17 ]
Xie, Y. [18 ]
Chen, X. [4 ,19 ]
Jiang, J. [6 ,20 ]
Zhao, P. [21 ]
Hou, J. [22 ]
Gao, Z. [23 ]
Fan, H. [24 ]
Ding, J. [25 ]
Ren, H. [1 ]
机构：
[1] Chongqing Med Univ, Infect Dis, Affiliated Hosp 2, Chongqing, Peoples R China
[2] Shanghai Jiao Tong Univ, Infect Dis, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 1, Harbin, Peoples R China
[4] Capital Med Univ, Int Med Dept, Beijing YouAn Hosp, Beijing, Peoples R China
[5] China Med Univ, Shengjing Hosp, Infect Dis, Shenyang, Peoples R China
[6] Guangxi Med Univ, Affiliated Hosp 1, Infect Dis, Nanning, Peoples R China
[7] Henan Prov Peoples Hosp, Infect Dis, Zhengzhou, Peoples R China
[8] Fudan Univ, Huashan Hosp, Infect Dis, Shanghai, Peoples R China
[9] Cent S Univ, Xiangya Hosp 2, Infect Dis, Changsha, Hunan, Peoples R China
[10] Fourth Mil Med Univ, Infect Dis, Tangdu Hosp, Xian, Peoples R China
[11] Ningxia Med Univ, Infect Dis, Gen Hosp, Yinchuan, Peoples R China
[12] Shenzhen Third Peoples Hosp, Liver Dis Dept, Shenzhen, Peoples R China
[13] Cent S Univ, Infect Dis, Xiangya Hosp, Changsha, Hunan, Peoples R China
[14] Guangxi Univ Chinese Med, Liver Dis Dept, Affiliated Hosp 1, Nanning, Peoples R China
[15] Guangdong Hosp Tradit Chinese Med, Liver Dis Dept, Guangzhou, Guangdong, Peoples R China
[16] Sichuan Univ, Infect Dis, West China Hosp, Chengdu, Peoples R China
[17] Sixth Peoples Hosp Hangzhou, Liver Dis Dept, Hangzhou, Zhejiang, Peoples R China
[18] Capital Med Univ, Beijing Ditan Hosp, Liver Dis Dept, Beijing, Peoples R China
[19] Guangdong Gen Hosp, Infect Dis, Guangzhou, Guangdong, Peoples R China
[20] Fujian Med Univ, Affiliated Hosp 1, Liver Dis Dept, Fuzhou, Peoples R China
[21] 302 Hosp PLA, Int Ctr Liver Dis Treatment, Beijing, Peoples R China
[22] Southern Med Univ, Nanfang Hosp, Infect Dis, Guangzhou, Guangdong, Peoples R China
[23] Sun Yat Sen Univ, Affiliated Hosp 3, Infect Dis, Guangzhou, Guangdong, Peoples R China
[24] Guangzhou Eighth Peoples Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China
[25] Ruian Peoples Hosp, Hepatol Unit, Ruian, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30842-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-175
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [21] NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS
    Gane, E.
    Jia, J.
    Han, K.
    Tanwandee, T.
    Chuang, W. L.
    Marcellin, P.
    Chan, H. L.
    Piratvisuth, T.
    Wat, C.
    Martins, E.
    Liaw, Y. -F.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S31 - S31
  • [22] PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2B FOR HBEAG-POSITIVE CHRONIC HEPATITIS B USING ON-TREATMENT HBSAG DECLINE
    Sonneveld, Milan J.
    Rijckborst, Vincent
    Boucher, Charles A.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2010, 52 (04) : 530A - 530A
  • [23] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR; AN INTERIM ANALYSIS
    Takkenberg, B.
    De Niet, A.
    Terpstra, V.
    Zaaijer, H.
    Weegink, C.
    Koot, M.
    Dijkgraaf, M.
    Jansen, P.
    Beld, M.
    Reesink, H.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S397 - S397
  • [24] HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study
    Hu, Peng
    Shang, Jia
    Zhang, Wenhong
    Gong, Guozhong
    Li, Yongguo
    Chen, Xinyue
    Jiang, Jianning
    Xie, Qing
    Dou, Xiaoguang
    Sun, Yongtao
    Li, Yufang
    Liu, Yingxia
    Liu, Guozhen
    Mao, Dewen
    Chi, Xiaoling
    Tang, Hong
    Li, Xiaoou
    Xie, Yao
    Chen, Xiaoping
    Jiang, Jiaji
    Zhao, Ping
    Hou, Jinlin
    Gao, Zhiliang
    Fan, Huimin
    Ding, Jiguang
    Zhang, Dazhi
    Ren, Hong
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 6 (01) : 25 - 34
  • [25] SERUM HBSAG LEVELS DURING PEGINTERFERON ALFA-2A TREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
    Kim, Bo Hyun
    Kim, Won
    Song, Fun Young
    Park, Myoung Hee
    Yoon, Jung-Hwan
    Lee, Youn Jae
    Park, Sung Jae
    Jung, Eun Uk
    Kim, Donghee
    Kim, Yoon Jun
    Lee, Hyo-Suk
    HEPATOLOGY, 2010, 52 (04) : 514A - 514A
  • [26] Significant reduction of HBsAg in the sera of HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2A alone or in combination with lamivudine
    Brunetto, Maurizia
    Bonino, Ferruccio
    Moriconi, Francesco
    Patrick, Marcellin
    George, Lau K.
    Patrizia, Farci
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, Kangxian
    Wang, Yuming
    Hadziyannis, Stephanos
    Wolf, Eva
    Matei, Popescu
    HEPATOLOGY, 2006, 44 (04) : 549A - 549A
  • [27] EARLY ON-TREATMENT HBSAG AND HBV DNA LEVELS IDENTIFY HBEAG-NEGATIVE PATIENTS NOT RESPONDING TO 48 OR 96 WEEKS OF PEGINTERFERON ALFA-2A THERAPY
    Rijckborst, Vincent
    Hansen, Bettina E.
    Ferenci, Peter
    Brunetto, Maurizio R.
    Tabak, Fehmi
    Cakaloglu, Yilmaz
    Lanza, Alfonso G.
    Messina, Vincenzo
    Iannacone, Claudio
    Massetto, Benedetto
    Martins, Eduardo B.
    Colombo, Massimo
    Janssen, Harry L.
    Lampertico, Pietro
    HEPATOLOGY, 2010, 52 (04) : 557A - 558A
  • [28] EARLY REDUCTION OF SERUM HBSAG LEVELS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS ACHIEVING SUSTAINED VIROLOGICAL RESPONSE AFTER PEGINTERFERON ALFA-2A ± RIBAVIRIN TREATMENT
    Rijckborst, Vincent
    ter Borg, Martijn J.
    Akarca, Ulus S.
    Grima, Piero
    Flisiak, Robert
    Vafiadis-Zouboulis, Irini
    Tripi, Silvio
    van Doornum, Gerard J.
    Verhey, Elke
    van Vuuren, Anneke J.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2008, 48 (04) : 749A - 750A
  • [29] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in chronic hepatitis B
    Fried, Michael W.
    Lau, George K. K.
    Liaw, Yun-Fan
    Luo, Kang-Xian
    Piratvisuth, Teerha
    Cooksley, Graham
    Marcellin, Patrick
    Thongsawat, Satawat
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A72 - A72
  • [30] RESPONSE PATTERNS OF CHINESE PATIENTS WITH CHRONIC HEPATITIS B WHO ACHIEVED HBSAG CLEARANCE THROUGH TREATMENT WITH PEGINTERFERON ALFA-2A
    Xue, Dao Zhan
    Chen, Yue
    Zhang, Wen-Hong
    HEPATOLOGY, 2008, 48 (04) : 734A - 734A
12345